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Abstract
Introduction: Renal cell carcinoma (RCC), regarded as the most lethal of all urological tumors, is relatively
uncommon. Recent reports from developed countries indicate a rising incidence, most likely from the
increasing availability of imaging services leading to an increase in incidental diagnosis of early stage
tumors, with consequently better prognosis. However, literature on RCC in sub-Saharan Africa is relatively
sparse.
Objectives: To determine the prevalence, presentation, pattern and outcome of RCC at the Lagos University
Teaching Hospital.
Methods: Information extracted from the records of 64 adult patients with RCC seen in our institution
between January 2000 and December 2010 included the age and sex of the patient, clinical features,
investigations, tumor stage, treatment, outcome of management and follow-up.
Results: The mean patient age was 41.8 years (range 20–75 years) with a male:female ratio of 1:1.7. Flank
mass, flank pain and hematuria were present in 90.6%, 86% and 40.6% of patients, respectively, whileal triad of loin pain, loin mass and hematuria. Only 1 patient (1.6%) had an
or stages T3 and T4 accounted for 93.7% of patients, while the clear cell type
ically examined cases. Forty-five patients (70.3%) had surgical intervention.
r follow-up, 50% were alive at 48 months, while all inoperable T4 and M1
p were dead within 1 year.36% of patients had the classic
incidental diagnosis. TNM tum
accounted for 60% of histolog
Of the T2 patients available fo
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Conclusion: RCC in our environment is characterized by a younger age at presentation, a female predom-
inance and clinical presentation at an advanced clinical stage.
© 2012 Production and hosting by Elsevier B.V. on behalf of Pan African Urological Surgeons’ Association.
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ND licIntroduction
Recent reports from developed countries indicate a rising incidence
of renal cell carcinoma (RCC), most likely from the increasing
availability of imaging services leading to an increase in inciden-
tal diagnoses [1]. RCC is a relatively uncommon malignancy in
Nigeria; while the world wide incidence is about 3.9/100.000 [2].
It is said to be rare in Africans and Asians, and accounts for more
than 31.000 new cases annually in the United States [3]. Earlier
reports by Lawani et al. in 1982 indicated that RCC accounted
for 20.9% of all urogenital tumors in Nigeria [4], whereas Klu-
fio recently reported that it accounted for 10.4% of all urogenital
tumors in Ghana [5]. In most developed countries, the evalua-
tion and management of RCC has evolved in recent decades in
response to the changing clinical presentation of the disease. Tra-
ditionally, patients with RCC presented with signs or symptoms
and the disease was usually locally advanced and often metastatic,
with a poor prognosis. In 1973 only 13% of cases in the USA
were diagnosed incidentally, compared to 61% in 1998 [6]. With
increasing use of axial body imaging in the evaluation of non-
specific abdominal complaints, currently more than 70% of RCC
cases are diagnosed incidentally, with consequent stage migration
toward smaller, organ-confined tumors appropriate for nephron-
sparing approaches, with the more favorable outcome [7,8]. In
contrast, earlier reports from Nigeria and other parts of Africa indi-
cated that these tumors were often diagnosed in advanced stages
because patients presented when they were moribund or unfit for
surgical intervention, with consequently poor prognosis even after
nephrectomy [9–11].
The present study was carried out at Lagos University Teaching Hos-
pital Idi-Araba, which provides specialized health care for Lagos
state, with 15 million residents and referrals from various parts
of Nigeria. It was undertaken to determine the prevalence, age,
sex distribution, current pattern of presentation, histological vari-
ants, management and treatment outcome of RCC in the Lagos
metropolis, and to compare the findings with other reports on this
disease.
Materials and methods
Between January 2000 and December 2010, 64 adults with RCC
seen in our institution were managed and followed up. Informa-
tion extracted from the patients’ records and analyzed included
the age, sex, clinical features, investigations, histological variants,
stage of the disease, treatment options, outcome of management and
follow-up. All patients were evaluated with at least an ultrasound
scan, computerized tomographic (CT) scan and chest X-ray. Other
investigations that were performed when indicated (and available)
included magnetic resonance imaging and image guided fine needle
Open access under CC BY-NC-aspiration cytology (FNAC). All patients that qualified for surgi-
cal intervention were operated via a transperitoneal approach. A
preliminary exploration was done to assess operability and confirm
preoperative findings.
(
a
a
(ll histology and cytology slides were reviewed by a single pathol-
gist (CCA). Hematoxylin and eosin (H&E) stained slides were
etrieved from the archives and where necessary new slides were
ade from stored paraffin embedded tissue blocks. Faded slides
ere re-stained and all slides were reviewed and diagnosis mod-
fied as appropriate. The tumors were classified according to the
HO classification of 2003 [12].
ollow-up was patient specific. As a rule, all patients who had
ndergone radical nephrectomy (RN) were scheduled to be fol-
owed up every 3 months for at least 1 year with reducing
requency later. Follow-up included disease related history, exam-
nation and routine ultrasound at 6 months for patients without
roblems.
esults
he mean patient age was 41.8 years (range 20–75 years), the peak
ge incidence was the 5th decade, followed by the 3rd decade. The
ale to female ratio was 1:1.7. Only 1 patient (1.6%) had a fam-
ly history of malignant renal tumor (mother) while 3 (4.7%) had
xposure to industrial dyes. A history of tobacco use ranging from 2
o 15 years was obtained in 7 patients (11%). Clinical presentation
ncluded hematuria in 26 patients (40.6%), loin pain in 55 (86%), a
alpable flank mass in 58 (90.6%) and the triad of hematuria, flank
ain and palpable mass in 23 (36%) patients. Hematuria was the first
ymptom in 16 patients (25%). Only 1 patient (1.6%) was asymp-
omatic and had the tumor detected during abdominal imaging for
nrelated symptoms. The tumor was located on the right side in 31
atients (48.4%), on the left side in 28 (43.8%) and bilaterally in 5
7.8%).
here was history of weight loss in 35 patients (54.7%) and 15
23%) were febrile at presentation. Anemia was present in 42.3%,
ight sweats in 7.7%, pedal oedema in 10 (15.6%) and 2 of 24 male
atients (8.3%) had an irreducible varicocele (one on the right and
ne on the left side). The time from onset of symptoms to the clinical
iagnosis of RCC ranged from one week to four years (average 12
onths).
he diagnosis of RCC was made on clinical features and CT findings
f a contrast enhancing solid renal mass in all patients. The diag-
osis was confirmed on histology from an operative specimen in 45
atients (70.3%), on FNAC in 11 (17.2%) patients with clinically
dvanced and inoperable disease, and on clinical and radiological
ndings alone in 8 (12.5%) patients with clinically advanced and
noperable tumors.
lear cell carcinoma accounted for 27 (60%) of the 45 patients
ith histopathology while the papillary subtype accounted for 12
ense.26.7%). Females accounted for 63% and 67% of the clear cell
nd papillary tumors, respectively. Collecting duct, sarcomatoid
nd chromophobe types accounted for 4 (8.9%), 1 (2.2%) and 1
2.2%), respectively. Seven of the 11 cases confirmed with FNAC
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ere characterized as clear cell type while the remaining 4 could
ot be characterized.
he clinical tumor stage was T2 in 4 (6.3%), T3 in 39 (60.9%) –
3a in 30 (46.9%), T3b in 7 (10.9%), T3c in 2 (3.1%) – and T4 in
1 (32.8%) of cases. There was clinical or radiological evidence of
egional lymph node enlargement in 33 (51%) and distant metastasis
n 23 patients (36%).
he treatment in 45 (70.3%) of the patients was surgery. In 4 of
hese patients the tumor was reported as inoperable because of
nfiltration into the surrounding structures, including the liver and
osterior abdominal wall. In these patients only tissue sampling
as performed, while the others underwent RN. Operative mortal-
ty was 6.3%—two patients died from excessive hemorrhage while
ne patient with vena cava thrombus died from massive pulmonary
mbolism. The mean diameter of the tumor removed was 22 cm
range 12–30 cm). Major post-operative complications included
ntra-abdominal bleeding necessitating re-exploration, wound infec-
ion, bowel injury, pancreatic injury, septicemia, and subacute
ntestinal obstruction. The remaining 19 patients were managed non-
peratively and referred to the oncology department. Main treatment
ffered included bevacizumab (avastin) in combination with inter-
eron alpha (if affordable) and other palliative measures including
adiotherapy.
verage follow-up was 10 months (range 3–52 months) and 42
67%) patients were lost to follow-up. Among the patients with T2
umors, 2 were alive at 4 years, 1 presented 12 months after RN with
etastases and died within a year while 1 was lost to follow-up after
2 months after RN. All the inoperable T4 and M1 patients available
or follow-up were dead in less than 1 year.
iscussion
CC is relatively uncommon and is reported to account for about
–3% of all adult cancers and 85% of all malignant kidney tumors
n Europe and America [3]. The biopsy records of the Department
f Morbid Anatomy of our hospital showed that RCC accounted
or only 3.7% of all urogenital tumors during the period of study.
his is in contrast to an earlier study from Ghana, which reported a
revalence of about 10.4% of all urogenital tumors [5]. The reasons
or this are not clear. Possible explanations may include the recent
ncrease in the diagnosis of prostate and cervical cancer as a result
f screening programs. Another possible explanation may be that a
atient with advanced RCC who is not fit for surgery may escape
issue diagnosis, as was the case in 12.5% of the patients in this
tudy.
CC was almost twice as common in females than males (M:F ratio
:1.7). This is contrary to most reports in the literature which indicate
male predominance [2]. The peak age of incidence in our study was
he 5th decade, which is similar to findings in other studies in our
nvironment and is at least one decade earlier than figures reported
n literature for Caucasians [2]. The second highest incidence in this
tudy was the 3rd decade. There is no clear explanation for this. The
verage life expectancy of about 48 years in Nigeria [13] may be a
ontributory factor, as there is a low proportion of elderly people in
he population.
he majority of the patients in this study did not have any of
he known predisposing factors for RCC. Even though tobacco
i
f
t
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moking is the only generally accepted environmental risk factor,
nly 5 (7.8%) of the patients gave a history of cigarette smoking of
years or more.
hereas in developed countries most cases of RCC are diagnosed
ncidentally on imaging, with consequently earlier stage at diagnosis
7,8,14,15], only 1 patient in our study had an incidental diagno-
is. Indeed, over 90% of the patients presented with Robson stage
or 4 disease, similar to the experience of others in sub-Saharan
frica [16]. This perhaps constitutes the greatest impediment to
ffective therapy in our environment. Patients often present with
pparently early stage disease, but after being informed of the need
or surgery, default with the aim of seeking alternate therapy with
raditional (alternative) health practitioners. These patients tend to
resent many months or years later with incurable disease, as was
he case with 7 patients in this study. Poverty and ignorance are con-
ributory factors, as is the practice of some general practitioners who
imply prescribe antibiotics or anti-schistosomal drugs for patients
ith hematuria, rather than to fully evaluate them. All the patients
xcept 1 in this study who had hematuria as their first symptom
ere treated with an antibiotic or anti-schistosomal drug without
ny imaging requested by the first attending physician.
n this study hematuria (40.6%), flank pain (86%) and flank mass
91.6%) were prominent symptoms of RCC. This “classical triad”,
hich often indicates incurable disease, is said to occur in less than
0% of patients in more developed countries [17] but was found
n 36% of our patients. In developed countries hematuria is the
ommonest symptom of RCC, whereas in our study loin pain and
oin mass were twice as common as hematuria, similar to the find-
ngs of others in our environment [11,16]. However, in patients
ho had hematuria, it was the earliest symptom in 62%. Signifi-
ant weight loss (50%) and severe anemia (42.3%) seen in these
atients were suggestive of advanced disease at presentation. Varic-
cele was present in 2 (8.3%) of 24 male patients, thus it is not a
ommon feature of RCC in our environment.
istological diagnosis was available in 70.3% of the patients who
ad surgical intervention while cytological diagnosis was available
n 17.2%. Even though the role of FNAC in the management of
CC is limited, it is useful in confirming the diagnosis in patients
ith advanced disease not fit for surgical intervention. It is possible
o identify the clear cell variant because the characteristics of the
ells are visible on cytology, as was the case in 7 patients in this
tudy. For the remaining 12.5% the diagnosis was based on clini-
al and radiological findings alone. These patients presented with
ocally advanced and metastatic disease. Ideally, tissue diagnosis is
egarded as the gold standard for the diagnosis of malignancy. How-
ver, even in asymptomatic RCC patients, modern cross-sectional
maging techniques are so accurate that false positive diagnoses are
ncommon [18]. In all the patients without tissue diagnosis in this
tudy the CT scan showed a contrast enhancing solid renal mass in
ddition to both radiological and clinical features of well-advanced
alignant disease.
CC is relatively resistant to radiotherapy and other forms of
ystemic therapy, therefore surgical excision is the mainstay of treat-
ent. For patients with operable tumors the treatment of choices RN, with removal of the diseased kidney outside of Gerota’s
ascia and adrenalectomy if the gland is involved. In this study,
he mean diameter of tumor removed was 22 cm. This contrasts
ith reports from developed countries with an average of 5–8 cm,
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but is consistent with the findings of Badmus et al. in Southwest
Nigeria [16]. Even though the current trend is toward nephron-
sparing and laparoscopic surgery, our patient characteristics and the
endemic infrastructural challenges make these options unrealistic.
Operative mortality in this study was 6.3%. This is higher than the
2.8% quoted in Western literature [19]. The late presentation by
patients in our environment may be responsible for this higher mor-
tality. Even though controversial, in our center RN is offered to all
RCC patients who are regarded as operable on imaging and consid-
ered fit for surgery, irrespective of the clinical stage. We have found
this useful in temporary symptom palliation. Likewise, patients with
apparently resectable T3 tumors with metastases deemed too ill to
undergo surgery were excluded from surgical intervention. Even
though T3b and T3c accounted for only 14.1% of all tumors, there
was radiological evidence of venous involvement in at least 25%
of all patients. Tumor thrombi with minimal IVC extension were
removed via the incision at the ostium of the renal vein. Due to
technical and infrastructural limitations we were not able to offer
surgery for patients with extensive IVC involvement. Two patients
died from excessive hemorrhage, while 1 patient died from massive
pulmonary embolism. Two of these 3 patients had T3b tumors.
Over the past 2 decades, the histological classification of RCC has
undergone significant changes. We have adopted the WHO classifi-
cation [12]. Clear cell RCC accounted for a majority of cases (about
60%), followed by the papillary sub-type (26.6%). This is consistent
with reports in the literature, even though most studies had given
figures of about 70–80% for clear cell and 10–15% for papillary
RCC [15,20]. Females accounted for the majority among all his-
tological groups. The reason for the relatively lower prevalence of
clear cell RCC in this study is unclear. However, in an earlier review
of patients with renal tumors by Badmus et al. in Ife, South-west
Nigeria, the clear cell type accounted for only 46.2% of all cases
RCC [16].
RCC is relatively resistant to chemotherapy and radiotherapy.
However, this was the principal method of palliative management
available for patients with advanced disease. Unfortunately, very few
patients were able to afford bevacizumab (avastin) and interferon
alpha, the main forms of therapy available in our environment.
Follow-up in this study was very poor, with 67% of patients lost
to follow-up, thereby making accurate conclusions on prognosis
impossible. This is not unusual, because of the lack of good follow-
up support infrastructure in our environment, such as transport and
communication. Our patients often travel long distances to obtain
specialist care and are totally responsible for the cost of their medical
care. As in most other reports, tumor stage was the most important
prognostic factor. All the patients with T4 and M1 tumors available
for follow-up were dead within 12 months, while 50% of those with
T2 tumors were alive at 48 months. The patient who had a distant
recurrence one year after RN for a T2 tumor had a collecting duct
histological type.In conclusion, patients with RCC in our environment are more likely
to be females, tend to present at an earlier age, but with late stage
disease and a subsequently poor prognosis. The clear cell variant
accounted for 60% of cases. Continuing medical education with
[23
pecial emphasis to increase the awareness of general medical prac-
itioners on the need for a thorough urological evaluation of patients
resenting with any form of hematuria, is recommended.
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